Personalized Cancer Medicines

Global Personalized Cancer Medicines Market to Reach US$393.4 Billion by 2030

The global market for Personalized Cancer Medicines estimated at US$215.1 Billion in the year 2024, is expected to reach US$393.4 Billion by 2030, growing at a CAGR of 10.6% over the analysis period 2024-2030. Personalized Medicine Diagnostics, one of the segments analyzed in the report, is expected to record a 12.2% CAGR and reach US$258.0 Billion by the end of the analysis period. Growth in the Personalized Medicine Therapeutics segment is estimated at 8.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$58.6 Billion While China is Forecast to Grow at 14.6% CAGR

The Personalized Cancer Medicines market in the U.S. is estimated at US$58.6 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$82.0 Billion by the year 2030 trailing a CAGR of 14.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.5% and 9.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.4% CAGR.

Global Personalized Cancer Medicines Market – Key Trends & Drivers Summarized

Why Is Personalized Cancer Medicine Redefining Therapeutic Pathways in Modern Oncology?

Personalized cancer medicine—also referred to as precision oncology—is revolutionizing cancer treatment by aligning therapeutic strategies with a patient’s genetic profile, tumor molecular characteristics, and immune landscape. Unlike conventional one-size-fits-all chemotherapy, personalized therapies target specific mutations, biomarkers, or pathways that drive tumor growth. This approach improves efficacy, reduces adverse effects, and enables more durable responses, particularly in treatment-resistant or rare cancer subtypes. The emergence of genomic sequencing, biomarker discovery, and companion diagnostics has made precision medicine a practical and increasingly accessible reality.

Oncology’s transition toward personalization is being driven by the success of targeted therapies (e.g., EGFR, BRAF, ALK inhibitors), immune checkpoint inhibitors guided by PD-L1 expression, and next-generation treatments like CAR-T and TCR-T therapies. Liquid biopsies, circulating tumor DNA (ctDNA) assays, and AI-assisted diagnostic platforms are enabling real-time tumor monitoring and therapy customization. This patient-centric model is shifting clinical paradigms—from tumor location to molecular subtype—transforming clinical trial designs, drug pipelines, and regulatory frameworks around the world.

How Are Genomic Technologies and Biomarker-Based Diagnostics Enabling Precision Therapies?

The backbone of personalized cancer medicine lies in high-throughput genomic profiling, which identifies actionable mutations and guides targeted intervention. Technologies such as next-generation sequencing (NGS), whole-exome sequencing, RNA expression profiling, and proteomic analysis are being used to stratify patients for optimal therapy matching. These platforms are routinely applied in clinical settings to test for mutations in genes like BRCA1/2, KRAS, HER2, and NTRK—informing drug selection or trial eligibility.

Companion diagnostics are playing a critical role in co-developing and validating therapies in tandem with targeted biomarker identification. AI and machine learning tools are being deployed to parse multi-omic data, identify rare mutation signatures, and simulate drug response. Moreover, real-time tumor profiling through liquid biopsy is enabling non-invasive monitoring of treatment response and early detection of resistance mechanisms. These technologies are reducing diagnostic delays, optimizing outcomes, and contributing to the emergence of adaptive therapy regimens in oncology.

Which Cancer Types and Healthcare Systems Are Leading in Precision Oncology Adoption?

Precision oncology is being adopted most aggressively in cancers with high mutational burden and well-characterized biomarkers. Lung cancer, melanoma, breast cancer, colorectal cancer, and hematologic malignancies (e.g., leukemia, lymphoma, multiple myeloma) are the most studied and treated using personalized approaches. Pediatric oncology, brain tumors, and rare cancers are also seeing breakthroughs through genome-guided treatments and repurposed targeted agents.

North America dominates in adoption due to advanced genomic infrastructure, payer coverage of molecular diagnostics, and strong biotech-pharma integration. Europe follows closely with national genome projects and centralized cancer registries supporting precision treatment pathways. Asia-Pacific, particularly China and Japan, is rapidly scaling genomic testing and personalized therapy access through public–private partnerships and oncology innovation hubs. Low- and middle-income countries are beginning to integrate precision oncology into cancer control strategies through regional centers of excellence, international collaborations, and funding from global health organizations.

What Is Driving Long-Term Growth and Strategic Innovation in Personalized Cancer Medicines?

The growth in the personalized cancer medicines market is driven by the convergence of genomic science, data analytics, regulatory evolution, and unmet clinical needs. As cancer becomes the leading cause of death in many countries, the demand for therapies that offer higher specificity, improved survival rates, and reduced systemic toxicity is growing. Payers and regulators are increasingly supporting biomarker-linked reimbursement, while biopharma companies are reorienting pipelines around genetically defined subgroups.

Strategically, investment is flowing into biomarker discovery, multi-omic data integration, and AI-based treatment planning tools. Collaborative ecosystems involving academic medical centers, genomic labs, startups, and global pharma are accelerating innovation in drug development and trial design. “Basket” and “umbrella” trials, real-world evidence (RWE) integration, and adaptive licensing models are enabling faster, data-rich product approvals. As oncology moves from population-based protocols to highly individualized treatment strategies, personalized cancer medicines will define the next frontier of therapeutic precision, patient empowerment, and oncology care transformation.

SCOPE OF STUDY:

The report analyzes the Personalized Cancer Medicines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product (Personalized Medicine Diagnostics, Personalized Medicine Therapeutics); End-Use (Hospitals & Clinics, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

• AC Immune
• Agenus
• AstraZeneca
• BioNTech
• Bristol Myers Squibb
• Caris Life Sciences
• Epigene Labs
• Foundation Medicine
• Gilead Sciences
• Immatics
• Merck & Co.
• Myriad Genetics
• Novartis
• Pfizer
• Precision Medicine Group
• Regeneron Pharmaceuticals
• Roche
• SimBioSys
• Tempus AI
• Umoja Biopharma

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.